German Prices Might Give Big Pharma a Headache This Earnings Season -- Market Talk
Dow Jones2026/10/20 07:290728 GMT - Germany's austerity measures might loom over big pharmaceutical companies when they report third-quarter results over the coming weeks, RBC Capital Markets analysts say in a research note. Johnson & Johnson's results last week showed German price declines weighed on sales of the U.S. drugmaker's Darzalex cancer drug, and other companies have flagged potential hits, the analysts say. Merck, Johnson & Johnson, Novartis, AstraZeneca and Roche have a higher exposure to Germany and oncology sales, according to RBC. The Stoxx Europe 600 Health Care index rises 0.9%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
October 20, 2026 03:29 ET (07:29 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.
Why Nintendo Stock Is One to Watch Ahead of the Holiday Season
A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.
Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.
Crypto prices
More
